Cargando…
预测贝伐珠单抗抗肿瘤治疗效果的生物学标记物
Bevacizumab, the monoclonal antibody of vascular endothelial growth factor (VEGF) has been applied to the therapy of several neoplasms, but an appropriate biomarker to predict the efficacy has not been found. Tose markers can originate from peripheral circulation, tumor tissue and genes. Some resear...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000279/ https://www.ncbi.nlm.nih.gov/pubmed/21762631 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.08 |